Skip to main content
Top
Published in: Medical Microbiology and Immunology 2-3/2022

Open Access 01-06-2022 | Tick | Original Investigation

Cytokine responses of immunosuppressed and immunocompetent patients with Neoehrlichia mikurensis infection

Authors: Linda Wass, Hanne Quarsten, Per-Eric Lindgren, Pia Forsberg, Elisabet Skoog, Kenneth Nilsson, Christine Lingblom, Christine Wennerås

Published in: Medical Microbiology and Immunology | Issue 2-3/2022

Login to get access

Abstract

Purpose

The tick-borne bacterium Neoehrlichia mikurensis causes the infectious disease neoehrlichiosis in humans. Vascular endothelium is one of the target cells of the infection. Neoehrlichiosis patients with compromised B cell immunity present with more severe inflammation than immunocompetent patients. The aim of this study was to compare the cytokine profiles of immunocompetent and immunosuppressed patients with neoehrlichiosis.

Methods

Blood samples from Swedish and Norwegian immunosuppressed (N = 30) and immunocompetent (N = 16) patients with neoehrlichiosis were analyzed for the levels of 30 cytokines, using a multiplex cytokine assay and ELISA. A gender-matched healthy control group (N = 14) was analyzed in parallel. Data were analyzed using the multivariate method OPLS-DA.

Results

The multiplex cytokine analyses generated more cytokine results than did the uniplex ELISA analyses. Multivariate analysis of the multiplex cytokine results established that increased levels of FGF2, GM-CSF, CXCL10, and IFN-γ were associated with immunosuppressed patients, whereas increased levels of IL-15 and VEGF were associated with immunocompetent neoehrlichiosis patients. When multivariate analysis findings were confirmed with uniplex ELISA, it was found that both groups of patients had similarly elevated levels of VEGF, FGF2 and IFN-γ. In contrast, the immunosuppressed patients had clearly elevated levels of CXCL10, CXCL13 and BAFF, whereas the immunocompetent patients had the same levels as healthy controls.

Conclusion

Pro-angiogenic and type 1 cytokines were produced as part of the host response of neoehrlichiosis independent of immune status, whereas immunosuppressed neoehrlichiosis patients produced cytokines required for B cell-mediated defense.
Literature
11.
go back to reference Dadgar A, Grankvist A, Wernbro L et al (2017) Fever of unknown origin in a multiple sclerosis patient on immunomodulatory therapy was due to neoehrlichiosis [Oklar feber hos patient med MS och rituximabbehandling var neoehrlichios - Ny fästingburen infektion som är svår att diagnostisera]. Lakartidningen. 114:6 Dadgar A, Grankvist A, Wernbro L et al (2017) Fever of unknown origin in a multiple sclerosis patient on immunomodulatory therapy was due to neoehrlichiosis [Oklar feber hos patient med MS och rituximab­behandling var neoehrlichios - Ny fästingburen infektion som är svår att diagnostisera]. Lakartidningen. 114:6
22.
go back to reference Barnewall RE, Rikihisa Y (1994) Abrogation of gamma interferon-induced inhibition of Ehrlichia chaffeensis infection in human monocytes with iron-transferrin. Infect Immun 62(11):4804–4810CrossRef Barnewall RE, Rikihisa Y (1994) Abrogation of gamma interferon-induced inhibition of Ehrlichia chaffeensis infection in human monocytes with iron-transferrin. Infect Immun 62(11):4804–4810CrossRef
25.
go back to reference Pulsatelli L, Boiardi L, Assirelli E et al (2020) Imbalance between angiogenic and anti-angiogenic factors in sera from patients with large-vessel vasculitis. Clin Exp Rheumatol. 124(2):23–30 Pulsatelli L, Boiardi L, Assirelli E et al (2020) Imbalance between angiogenic and anti-angiogenic factors in sera from patients with large-vessel vasculitis. Clin Exp Rheumatol. 124(2):23–30
Metadata
Title
Cytokine responses of immunosuppressed and immunocompetent patients with Neoehrlichia mikurensis infection
Authors
Linda Wass
Hanne Quarsten
Per-Eric Lindgren
Pia Forsberg
Elisabet Skoog
Kenneth Nilsson
Christine Lingblom
Christine Wennerås
Publication date
01-06-2022
Publisher
Springer Berlin Heidelberg
Published in
Medical Microbiology and Immunology / Issue 2-3/2022
Print ISSN: 0300-8584
Electronic ISSN: 1432-1831
DOI
https://doi.org/10.1007/s00430-022-00737-6

Other articles of this Issue 2-3/2022

Medical Microbiology and Immunology 2-3/2022 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.